



## Qtern<sup>®</sup> (dapagliflozin/saxagliptin) – Expanded indication

- On May 2, 2019, the FDA approved [Qtern \(dapagliflozin/saxagliptin\)](#) as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.
  - Previously, Qtern was indicated for use in adults with T2DM who have inadequate control with dapagliflozin or who are already treated with dapagliflozin and saxagliptin.
  - Qtern is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
- Dapagliflozin and saxagliptin in combination with metformin has been studied in adult patients with T2DM inadequately controlled on metformin. Treatment with dapagliflozin and saxagliptin and metformin (combination or add-on therapy) at all doses produced statistically significant improvements in HbA1c compared to the active comparator or placebo study arms in combination with metformin.
- For patients not already taking dapagliflozin, the recommended starting dose of Qtern is a 5 mg dapagliflozin/5 mg saxagliptin tablet taken orally once daily in the morning with or without food.
  - In patients tolerating 5 mg dapagliflozin and 5 mg saxagliptin once daily who require additional glycemic control, the Qtern dose can be increased to 10 mg dapagliflozin/5 mg saxagliptin tablet once daily.
  - Qtern should be swallowed whole.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.